Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4556-4560

  Hansen Algenstaedt, Nils ^a   Stoll, Brian R ^a,b   Padera, Timothy P ^a,b   Dolmans, Dennis E J G J ^a   Hicklin, Daniel J ^c   Fukumura, Dai ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION; CONTROLLED STUDY; HYPOXIA; IMMUNE DEFICIENCY; MALE; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TENSION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION;

ANDROGENS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; LUMINESCENT MEASUREMENTS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; OXYGEN; OXYGEN CONSUMPTION; PARTIAL PRESSURE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0034662621     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
2. 2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation
3. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
4. Hypoxia and drug resistance
5. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
6. Tumor induction of VEGF promoter activity in stromal cells
7. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
8. The biology of vascular endothelial growth factor
9. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
10. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
11. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
12. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
13. Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy
14. Combined effects of angiostatin and ionizing radiation in antitumour therapy
15. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
16. Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system
17. The role of tumor volume in "reoxygenation" upon cyclophosphamide treatment
18. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice
19. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody
20. Quantitation and gompertzian analysis of tumor growth
21. 2 measurements by phosphorescence decay method
22. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours
23. Method for the determination of oxygen consumption rates and diffusion coefficients in multicellular spheroids
24. 2-histography
25. The histological structure of some human lung cancers and the possible implications for radiotherapy
26. Microvascular and tissue oxygen gradients in the rat mesentery
27. Growth factors: Formation of endothelial cell networks
28. Mammary tumor regression. III. Uptake and loss of substrates by regressing tumors
29. The oxygen effect and reoxygenation
30. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay
31. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
32. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
33. Oxygen delivery: Implications for the biology and therapy of solid tumors